Citadel Advisors
IMNM icon

Citadel Advisors’s Immunome IMNM Stock Holding History

Citadel Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Sell
58,000
-13,900
-19% -$297K ﹤0.01% 7700
2026
Q1 		$1.57M Sell
71,900
-19,900
-22% -$443K ﹤0.01% 6611
2025
Q4 		$1.97M Buy
91,800
+37,500
+69% +$658K ﹤0.01% 5945
2025
Q3 		$636K Buy
54,300
+32,700
+151% +$325K ﹤0.01% 8549
2025
Q2 		$201K Buy
21,600
+6,000
+38% +$49.2K ﹤0.01% 10670
2025
Q1 		$105K Sell
15,600
-5,500
-26% -$52.8K ﹤0.01% 11382
2024
Q4 		$224K Sell
21,100
-17,000
-45% -$205K ﹤0.01% 10238
2024
Q3 		$557K Buy
38,100
+10,000
+36% +$142K ﹤0.01% 8035
2024
Q2 		$340K Buy
28,100
+6,700
+31% +$105K ﹤0.01% 8890
2024
Q1 		$528K Buy
21,400
+11,700
+121% +$237K ﹤0.01% 8277
2023
Q4 		$104K Buy
9,700
+4,000
+70% +$33.3K ﹤0.01% 10888
2023
Q3 		$47.6K Sell
5,700
-11,300
-66% -$83K ﹤0.01% 11816
2023
Q2 		$134K Buy
17,000
+8,100
+91% +$44.3K ﹤0.01% 10495
2023
Q1 		$44.4K Buy
+8,900
New +$43.5K ﹤0.01% 12314
2022
Q4 		– Sell
-26,500
Closed -$118K – 15151
2022
Q3 		$118K Sell
26,500
-15,600
-37% -$73.1K ﹤0.01% 10953
2022
Q2 		$135K Buy
42,100
+6,600
+19% +$24K ﹤0.01% 11090
2022
Q1 		$202K Sell
35,500
-13,100
-27% -$97.9K ﹤0.01% 11513
2021
Q4 		$630K Buy
48,600
+10,400
+27% +$185K ﹤0.01% 9099
2021
Q3 		$930K Buy
+38,200
New +$666K ﹤0.01% 8336

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Citadel Advisors's IMNM Position: Q2 2026 in Review

Citadel Advisors increased its Immunome (IMNM) stake by 179% in Q2 2026, buying an estimated $3.08M and bringing the position to 224,079 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4811.

Citadel Advisors first reported a position in IMNM in Q3 2021 and has held it in 14 quarters since. The position peaked at $37.4M in Q4 2025. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Citadel Advisors held 224,079 shares of Immunome worth $4.75M as of Q2 2026.
  • Citadel Advisors bought 143,882 Immunome shares in Q2 2026, an estimated $3.08M.
  • Immunome made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4811 holding.
  • Citadel Advisors first reported a position in Immunome in Q3 2021 and has held it in 14 quarters since.
  • Citadel Advisors's Immunome position peaked at $37.4M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.